The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Research Grant, 2010Longitudinal Follow-Up of Clinical and Neuroimaging Signs and Biomarkers in Symptoms & Side Effects and aSymptoms & Side Effects LRRK2 Mutation Carriers in Comparison to Idiopathic PD and Controls
Objective/Rationale:
Parkinson’s disease (PD) is a common neurodegenerative disease that leads to progressive motor impairment as well as autonomic and cognitive disturbances. The cause of most of... -
Alpha-Synuclein Therapeutics, 2010Testing of Davunetide for Intranasal Administration in Pre-clinical Models Over Expressing Alpha-synuclein
Objective/Rationale:
Davunetide is an investigational drug with the potential to treat Parkinson disease and is currently in a clinical trial for progressive supranuclear palsy, a rare progressive... -
Rapid Response Innovation Awards, 2010Ghrelin - a Peripheral, Preclinical Biomarker for Parkinson's Disease
Promising Outcomes of Original Grant:
In our original grant we investigated serum concentrations of the hormone ghrelin in the fasting state and at different time points after a standardized test meal... -
Biomarkers, 2010Prospective Validation of Risk Markers for the Development of Parkinson’s Disease
Promising Outcomes of Original Grant:
As Parkinson’s disease is diagnosed when already a number of neurons have degenerated the PRIPS cohort consisting of 1847 healthy subjects older than 50 years was... -
Rapid Response Innovation Awards, 2009Enhanced Delivery of Viral Vectors to Striatum with Solid-State Biodegradable Matrices
Objective/Rationale:
When treating patients with neurological disorders, physicians frequently administer drugs through a small plastic tube or needle placed into the target area of the brain... -
Clinical Intervention Awards, 2009NIC-PD Trial to Assess the Disease-modifying Potential of Transdermal Nicotine in Early Parkinson's Disease
Objective/Rationale:
No drugs are available that can slow or stop the progression of Parkinson’s disease (PD). Nicotine is a promising substance for this purpose. Firstly, epidemiological studies...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.